Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SI-B036 in Advanced Breast Cancer and Solid Tumors
NCT07753226Phase 1Recruiting
- Sponsor
- Biokin Pharmaceutical
- Start
- Aug 2026
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SI-B036 in breast cancer and solid tumor, sponsored by Biokin Pharmaceutical. Primary endpoints: Dose Limiting Toxicity, Maximum Tolerated Dose and 1 more. Started Aug 2026; status: recruiting.
02
Drugs
SI-B036
03
Conditions
breast cancersolid tumor
Beyond the preview
Go deeper on NCT07753226.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07753226.